ERBB2 and neoplasm: Examining the data separately by tumor subtype and cT staging, it appears that the choice rates between lumpectomy and mastectomy varied among Luminal A, Luminal B HER2-, HER2+, and triple negative subtypes (22.2% vs. 43.6% vs. 32.4% vs. 36.5%) and among different cT staging categories (p < 0.001 for the comparison between cT1, cT2, and cT3, 53.3% vs. 39.9% vs. 15.0%) [1].